CN117801968A - Genetically engineered bacterium for over-expressing phosphorylcholine cytidine transferase gene, construction method and application thereof - Google Patents
Genetically engineered bacterium for over-expressing phosphorylcholine cytidine transferase gene, construction method and application thereof Download PDFInfo
- Publication number
- CN117801968A CN117801968A CN202311560651.1A CN202311560651A CN117801968A CN 117801968 A CN117801968 A CN 117801968A CN 202311560651 A CN202311560651 A CN 202311560651A CN 117801968 A CN117801968 A CN 117801968A
- Authority
- CN
- China
- Prior art keywords
- phosphorylcholine
- cct
- transferase gene
- genetically engineered
- expressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 32
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 title claims abstract description 27
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 title claims abstract description 27
- 108090000992 Transferases Proteins 0.000 title claims abstract description 27
- 229950004354 phosphorylcholine Drugs 0.000 title claims abstract description 26
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 title claims abstract description 23
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 title claims abstract description 13
- 238000010276 construction Methods 0.000 title abstract description 9
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 27
- 241000003595 Aurantiochytrium limacinum Species 0.000 claims abstract description 24
- 241000598397 Schizochytrium sp. Species 0.000 claims abstract description 4
- 239000002773 nucleotide Substances 0.000 claims abstract description 4
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 4
- 239000001963 growth medium Substances 0.000 claims description 26
- 238000011218 seed culture Methods 0.000 claims description 22
- 238000000855 fermentation Methods 0.000 claims description 20
- 230000004151 fermentation Effects 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 14
- 238000012258 culturing Methods 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 230000002018 overexpression Effects 0.000 claims description 11
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 9
- 239000000194 fatty acid Substances 0.000 claims description 9
- 229930195729 fatty acid Natural products 0.000 claims description 9
- 150000004665 fatty acids Chemical class 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 238000004458 analytical method Methods 0.000 claims description 8
- 230000006801 homologous recombination Effects 0.000 claims description 7
- 238000002744 homologous recombination Methods 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 108010006654 Bleomycin Proteins 0.000 claims description 6
- 229960001561 bleomycin Drugs 0.000 claims description 6
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 6
- 239000002054 inoculum Substances 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 5
- 241001052560 Thallis Species 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 230000004060 metabolic process Effects 0.000 claims description 3
- 238000005070 sampling Methods 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 abstract description 17
- 239000004519 grease Substances 0.000 abstract description 9
- 238000009825 accumulation Methods 0.000 abstract description 6
- 238000010353 genetic engineering Methods 0.000 abstract description 5
- 102000004357 Transferases Human genes 0.000 abstract description 4
- 230000001105 regulatory effect Effects 0.000 abstract description 4
- 230000001276 controlling effect Effects 0.000 abstract description 3
- 230000004136 fatty acid synthesis Effects 0.000 abstract description 3
- 108700026220 vif Genes Proteins 0.000 abstract 1
- 241000233671 Schizochytrium Species 0.000 description 25
- YHHSONZFOIEMCP-UHFFFAOYSA-N 2-(trimethylazaniumyl)ethyl hydrogen phosphate Chemical compound C[N+](C)(C)CCOP(O)([O-])=O YHHSONZFOIEMCP-UHFFFAOYSA-N 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 6
- 239000002028 Biomass Substances 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
- 150000003905 phosphatidylinositols Chemical class 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 3
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 150000001982 diacylglycerols Chemical class 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 238000003208 gene overexpression Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 108010083912 bleomycin N-acetyltransferase Proteins 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 102100036869 Diacylglycerol O-acyltransferase 1 Human genes 0.000 description 1
- 108050004099 Diacylglycerol O-acyltransferase 1 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 241001274216 Naso Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 101710133727 Phospholipid:diacylglycerol acyltransferase Proteins 0.000 description 1
- 108010030975 Polyketide Synthases Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 108700026846 bacteria SR Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides a genetic engineering bacterium for over-expressing a phosphorylcholine cytidine transferase gene, a construction method and application thereof, wherein the genetic engineering bacterium is obtained by over-expressing the phosphorylcholine cytidine transferase gene CCT in a starting bacterium; the starting strain is schizochytrium sp 21; the nucleotide sequence of the phosphorylcholine cytidine transferase gene is shown as SEQ ID NO: 1. The total grease and phospholipid content of the engineering bacteria are obviously increased, the accumulation of polyunsaturated fatty acids is increased, the grease content is increased by 20% and the PUFAs content is increased by 15% under the condition of keeping the dry weight of cells unchanged, and theoretical basis is provided for regulating and controlling schizochytrium limacinum to improve fatty acid synthesis.
Description
Technical Field
The invention belongs to the technical field of bioengineering, and particularly relates to a genetically engineered bacterium for over-expressing a phosphorylcholine cytidine transferase gene, and a construction method and application thereof.
Background
Schizochytrium sp is a marine fungus capable of synthesizing various beneficial active substances, such as fatty acids, squalene, pigments (lutein, astaxanthin, carotenoids) and the like. The oil content of the microbial strain can reach more than 50% of that of dry fungus cells, and the proportion of polyunsaturated fatty acids (PUFAs) in the total lipid can reach 40% -70%.
PUFAs are mainly produced by the anaerobic pathway of polyketide synthases, released as free fatty acids and accumulated in polar phospholipids such as Phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylglycerol (PG) or Phosphatidylinositol (PI), and eventually migrate to nonpolar lipids such as Diacylglycerol (DAG) or Triacylglycerol (TAG) for storage.
In the related art, the regulation and control of polyunsaturated fatty acids (PUFAs) produced by schizochytrium is mainly focused on the regulation and control by using a regulator in the fermentation process, and the regulation and control mode is limited.
At present, the research on phosphorylcholine cytidine transferase (CCT) is limited, mainly focused on animal organs and insects, and has not been reported in the field of genetic engineering of schizochytrium.
Disclosure of Invention
The invention aims to solve at least one of the technical problems in the technology to a certain extent, and provides a genetically engineered bacterium for over-expressing phosphorylcholine cytidine transferase gene, and a construction method and application thereof. The schizochytrium Schizochytrium limacinum SR is taken as an original strain, and the phospholipid metabolic pathway is modified to promote the synthesis of grease and the accumulation of polyunsaturated fatty acids.
Therefore, in an embodiment of the present invention, the present invention proposes, in a first aspect, a genetically engineered bacterium that overexpresses a phosphorylcholine cytidine transferase gene, wherein the genetically engineered bacterium is obtained by overexpressing a phosphorylcholine cytidine transferase gene CCT in a starting bacterium; the starting strain is schizochytrium sp 21; the nucleotide sequence of the phosphorylcholine cytidine transferase gene is shown as SEQ ID NO: 1.
According to the embodiment of the invention, the phospholipid content in the engineering bacteria is greatly improved. In schizochytrium, PUFAs bind to phospholipids and are then transferred to DAG and TAG by enzymes such as PDAT, PDCT and DGAT. Therefore, by over-expressing the phosphocholine cytidine transferase gene CCT to improve phospholipid metabolism, the synthesis of grease and the accumulation of PUFAs are obviously promoted, the content of grease is increased by 20 percent, and the content of PUFAs is increased by 15 percent under the condition of keeping the dry weight of cells unchanged.
The invention provides a construction method of the genetically engineered bacterium in a second aspect, which comprises the following steps:
(1) S.limacinum SR21 genomic DNA is used as a template, and SEQ ID NO:2 and SEQ ID NO:3, PCR amplifying the phosphorylcholine cytidine transferase gene CCT by using the sequence shown in the formula 3 as a primer;
(2) Inserting the phosphorylcholine cytidine transferase gene CCT into a homologous recombination region of a pBlue-zeo-18sUD overexpression vector, and constructing a CCT overexpression vector pBlue-zeo-18sUD-CCT with bleomycin as resistance;
(3) Linearizing the homologous recombination region of the overexpression vector pBlue-zeo-18sUD-CCT, electrically converting into the genome of S.limacinum SR21 for homologous recombination, and screening and identifying the resistance of bleomycin to obtain the genetically engineered bacterium SR21 over-expressing the CCT gene.
According to the embodiment of the invention, a key step of phospholipid pathway construction-phosphorylcholine cytidine transferase (CCT) gene overexpression vector is established in escherichia coli based on a genetic engineering means, then an expression frame with bleomycin resistance screening genes is inserted into an 18sDNA locus of an SR21 genome to construct schizochytrium engineering bacteria, the total grease and phospholipid content of the engineering bacteria are obviously increased, polyunsaturated fatty acid accumulation is increased, and a theoretical basis is provided for regulating and controlling schizochytrium to improve fatty acid synthesis.
In a second aspect of the invention, the use of the genetically engineered bacterium over-expressing a phosphorylcholine cytidine transferase gene in the production of fatty acids is provided.
In a third aspect of the present invention, there is provided a method for enhancing schizochytrium limacinum phospholipid metabolism to increase fatty acid production, comprising inoculating the genetically engineered bacterium overexpressing a phosphorylcholine cytidine transferase gene described above to a seed culture medium for activation to obtain a fermentation strain; inoculating the fermentation strain into a fermentation culture medium for fermentation culture, and collecting thalli for identification and analysis of oil components.
Optionally, streaking the genetically engineered bacteria over-expressing the phosphorylcholine cytidine transferase gene on a solid seed culture medium, and carrying out stationary culture at the temperature of 27-29 ℃; selecting a monoclonal on a flat plate to a liquid seed culture medium, and culturing at the temperature of 27-29 ℃ and the speed of 200-250 rpm to obtain first-stage seeds; inoculating the primary seeds into a new liquid seed culture medium according to the inoculum size of 4% -8%, and culturing at the temperature of 27-29 ℃ and the speed of 200-250 rpm to obtain secondary seeds; inoculating the secondary seeds into a fermentation culture medium in an inoculum size of 4% -8%, culturing for 120 hours at the temperature of 27-29 ℃ and the rpm of 200-250 rpm, and sampling every 24 hours in the culturing process for relevant analysis.
Additional aspects and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention.
Drawings
FIG. 1 is a schematic diagram of a gene overexpression vector pBlue-zeo-18sUD-CCT in the examples of the present invention;
FIG. 2 is an agarose gel electrophoresis diagram of the identification of the genetically engineered strain according to the embodiment of the invention;
FIG. 3 shows the results of CCT fermentation biomass and oil weight of the S.limacinum SR21 and the genetically engineered strain SR21 of the embodiment of the invention;
FIG. 4 shows the ratio of CCT polar oil to nonpolar oil of a wild strain of S.limacinum SR21 to a genetically engineered strain SR21;
FIG. 5 shows the fatty acid content change of S.limacinum SR21 wild-type strain and genetically engineered strain SR21 of the embodiment of the invention;
FIG. 6 shows the change of important phospholipid content of S.limacinum SR21 wild-type strain and genetically engineered strain SR21 of the embodiment of the invention, wherein the CCT is changed in 72 hours and 120 hours.
Detailed Description
Embodiments of the present invention are described in detail below, examples of which are illustrated in the accompanying drawings, wherein like or similar reference numerals refer to like or similar elements or elements having like or similar functions throughout. The embodiments described below by referring to the drawings are illustrative and intended to explain the present invention and should not be construed as limiting the invention.
The following disclosure provides many different embodiments, or examples, for implementing different embodiments of the invention. In order to simplify the present disclosure, specific embodiments or examples are described below. Of course, they are merely examples and are not intended to limit the invention. In addition, one of ordinary skill in the art will recognize the applicability of other processes and/or the use of other materials, as examples of the various specific processes and materials provided by the present invention. The practice of the present invention will employ, unless otherwise indicated, conventional techniques in the fields of chemistry, molecular biology, etc., which are within the ability of a person skilled in the art. In addition, unless otherwise indicated, herein, nucleic acids are written in a5 'to 3' direction from left to right, and amino acid sequences are written in an amino-to carboxy-terminal direction from left to right.
In the following examples, the following examples were carried out:
the formula of the solid seed culture medium is as follows: 30-35 g/L glucose, 8-11 g/L yeast powder, 50-52 mL 20 Xcomponent A, 500 XCaCl 2 1.5-2.5 mL, 15-20 g/L of agar, and regulating the pH value to 6.4-6.6.
The formula of the liquid seed culture medium is as follows: 30-35 g/L glucose, 8-11 g/L yeast powder, 50-52 mL 20 Xcomponent A, 500 XCaCl 2 1.5 to 2.5mL, and the pH value is adjusted to 6.4 to 6.6.
The formula of the fermentation medium is as follows: glucose 89-92 g/L, corn steep liquor 4-6 g/L, tryptone 4-6 g/L, 20 Xcomponent A48-52 mL, 500 XCaCl 2 2mL, and the pH is adjusted to 6.4-6.6.
The formula of the 20X component A is as follows: naSO (Naso-doped sodium sulfonate) 4 238~242g/L,MgSO 4 38~42g/L,(NH 4 ) 2 SO 4 19~21g/L,KH 2 PO 4 19~21g/L,K 2 SO 4 12~14g/L,KCl 9~11g/L;
500×CaCl 2 The formula is as follows: caCl (CaCl) 2 ·2H 2 O 83~87g/L。
The whole period of fermentation culture is 120h, and sampling detection is carried out every 24 h.
Schizochytrium s.limacinum SR21 was purchased from the american type culture collection (ATCC, USA).
The invention is described below by way of illustrative specific examples, which are not intended to limit the scope of the invention in any way. Specifically described are: the reagents used in the present invention are commercially available unless otherwise specified.
EXAMPLE 1 construction of the overexpression vector pBlue-zeo-18sUD-CCT
1. PCR amplification of CCT genes
Designing an amplification primer CCT-F/CCT-R according to the sequence information of the CCT gene of schizochytrium limacinum SR21, and then obtaining the CCT gene by using PrimeStar high-fidelity polymerase and the primer and adopting a PCR mode by taking the S.limocinum SR21 wild strain gene as a template, wherein the nucleotide sequence of the CCT gene is shown as SEQ ID NO: 1.
CCT-F:TGCTCTAGAC CTTCAAAGCA CTTCCCAG(SEQ ID NO:2);
CCT-R:CCGCTCGAGA TCGACAAAAA CAAAAGAATT GGA(SEQ ID NO:3);
The PCR reaction system is shown in the following table:
PCR reaction procedure is shown in the following Table
2. Construction of the overexpression vector pBlue-zeo-18sUD-CCT
The vector pBlue-zeo-18sUD and the CCT gene obtained above were double digested with restriction enzymes at 37℃for 2h.
The double enzyme digestion system is shown in the following table
The CCT gene was ligated to the vector pBlue-zeo-18sUD fragment using T4 ligase and reacted at 16℃for 12 hours.
The connection system is shown in the following table
The ligation product was transformed into E.coli DH 5. Alpha. Competent cells to obtain the overexpression vector pBlue-zeo-18sUD-CCT (refer to FIG. 1). The transformation method is as follows:
the ligation product was precooled on ice.
Competent E.coli (100. Mu.L) stored in an ultra-low temperature refrigerator at-80℃was removed and placed on ice for 10min.
mu.L of the ligation product was pipetted into competent E.coli, mixed well and placed on ice for 30min.
The mixture of ligation product and E.coli competent cells was placed in a water bath at 42℃for 45 to 90 seconds. Immediately after the completion of the reaction, the mixture was placed on ice for 2 minutes to 3 minutes.
900. Mu.L of E.coli LB liquid medium was added to the above ice-bathed competent cells, and the mixture was subjected to shaking culture at 37℃and 200rpm for 1 hour.
100. Mu.L of the bacterial liquid was aspirated from the shake flask containing competent cells after 1 hour of culture, and the culture was performed on a plate (E.coli LB solid medium) containing an antibiotic (bleomycin) at 37℃for 12 hours to 16 hours.
Example 2 construction of genetically engineered Strain SR 21::: CCT
Extracting the overexpression vector pBlue-zeo-18sUD-CCT, linearizing and recovering with restriction endonuclease Not I, transferring electric shock into schizochytrium competence for homologous recombination, coating bleomycin (Zeocin) resistance plates, culturing at 28 ℃ for 3-5d, and screening transformants. After genomic extraction, transformants were verified by PCR (as shown in fig. 2). Thus obtaining schizochytrium engineering bacteria SR21 over-expressing CCT genes.
Preparation of schizochytrium competence:
(1) Selecting schizochytrium single colony to 10mL of schizochytrium basal liquid seed culture medium, culturing for 24 hours at 28 ℃ in a shaking table at 200rpm, and transferring 50mL of liquid seed culture medium according to 4% of inoculum size for culturing for 20 hours;
(2) Taking 10mL of bacterial liquid, and centrifuging at a rotating speed of 4000 Xg under the condition of room temperature to obtain bacterial cells;
(3) Then treated with 25mM DTT in PBS for 30min, and centrifuged to discard the supernatant at 4 ℃;
(4) Respectively cleaning thalli twice by using precooled sterile water and precooled sorbitol solution;
(5) The cells were resuspended in an appropriate amount of sorbitol solution and then sub-packaged in sterilized 1.5mL centrifuge tubes, 100. Mu.L per tube, and placed on ice for use.
Electric conversion of schizochytrium:
(1) Mixing 100 μl schizochytrium competent cells and about 10 to 15 μl of the ligation product (about 3 to 5 μg) uniformly, transferring to a pre-chilled electric shock cup, placing in ice bath for 30min, and then shocking for 6 ms at 2KV for one pulse;
(2) Sucking 1mL of schizochytrium basal liquid seed culture medium, adding the schizochytrium basal liquid seed culture medium into an electric rotating cup, fully and uniformly mixing the culture medium and the electric rotated schizochytrium, transferring the mixture to a sterile 1.5mL centrifuge tube, and culturing the mixture in a shaking table at 28 ℃ and 200rpm for 2 to 3 hours;
(3) After the bacterial liquid is centrifuged and the supernatant is discarded, the bacterial liquid is coated on schizochytrium basal solid seed culture medium containing antibiotics and is cultured for 3 to 5 days in a constant temperature incubator at 28 ℃.
Example 3 identification analysis of schizochytrium engineering bacteria SR 21::: CCT
1. Cultivation of schizochytrium:
(1) CCT and schizochytrium original bacteria (schizochytrium S.limocinum SR 21) seeds preserved at-80 ℃ are streaked on a solid seed culture medium, and are cultured for 36 hours at 28 ℃;
(2) First-stage seed: selecting high-quality monoclonal on the cultured solid seed culture medium, and culturing in 10mL seed culture medium at 28 ℃ and 200rpm for 24-36 h;
(3) Secondary seed: 2mL of the primary seed culture medium is sucked and transferred into 50mL of the seed culture medium, and the primary seed culture medium is cultured for 20 to 24 hours at the temperature of 28 ℃ and the rpm of 200 rpm;
(4) Shaking and fermenting: from the secondary seed medium, a certain amount of seed culture solution was transferred to 50mL of fermentation medium at an inoculum size of 8%, and cultured at 28℃and 200rpm for 144 hours.
2. Measurement of the biomass:
(1) 1mL of the fermentation broth was accurately aspirated, added to a 1.5mL centrifuge tube that had been weighed in advance, centrifuged in a centrifuge at 10000 Xg for 2 minutes at room temperature, and then the supernatant was decanted.
(2) The cells were washed by air-sucking and mixing with 1mL of physiological saline, centrifuged at 10000 Xg for 2 minutes at room temperature in a centrifuge, and then the supernatant was discarded.
(3) Repeating the operation step (2) once.
(4) The samples were placed in a vacuum freeze dryer and after 24 hours of freeze drying, the centrifuge tube was removed and weighed. Biomass is calculated.
As shown in FIG. 3, the biomass of S.limacinum SR21 was always higher than that of the mutant with the increase of the culture time, and the difference was maximum at 72 hours, which was about 24.3% higher. The turning points of the wild type and SR21, which are respectively 72h and 96h when CCT enters the later growth stage, but the biomass tends to be the same at 144h, about 37.7g/L.
3. Determination of total oil content:
(1) 5mL of fermentation broth is taken into a50 mL centrifuge tube, and 5mL of hydrochloric acid is added into the centrifuge tube and heated at the constant temperature of 65 ℃ for 1h until the thalli are completely digested.
(2) The centrifuge tube was removed and after cooling to room temperature, 15mL of n-hexane was added for three extractions, and the upper organic phase was taken into a weighed 50mL centrifuge tube.
(3) The centrifuge tube was purged with nitrogen to evaporate the hexane.
(4) And taking out the centrifuge tube, cooling to room temperature, and weighing, wherein the weight of the empty centrifuge tube is subtracted from the weight of the centrifuge tube to obtain the total grease yield.
As shown in FIG. 3, the total oil weight of the S.limacinum SR21 is higher than that of SR21:: CCT only for 96 hours, the total oil yield of the SR21:: CCT is increased by about 31.23%, the total oil yield of the SR21:: CCT is higher than that of the wild type at other times, the total oil reaches the maximum value for 120 hours, and the total oil yield is increased by about 17.80%.
4. Determination of fatty acid content
(1) To the oil obtained in step 3, 5mL of 0.5M KOH-CH was added 3 And (3) placing the centrifuge tube in a constant-temperature water bath kettle at 65 ℃ for heating for 10min until the grease is completely dissolved.
(2) After the centrifuge tube was taken out and cooled to room temperature, 5mL of 30% boron trifluoride diethyl etherate was added to the centrifuge tube, and the centrifuge tube was heated in a 65℃thermostat water bath for 30min.
(3) Taking out the centrifuge tube, cooling to room temperature, adding 5mL of normal hexane, shaking, mixing uniformly, adding 1mL of saturated sodium chloride solution to prevent emulsification, standing for 5min, and layering.
(4) The upper organic phase was pipetted into a 5mL centrifuge tube containing an appropriate amount of anhydrous sodium sulfate for dehydration.
(5) The solution in the 5mL centrifuge tube was filtered through a 0.22 μm organic filter and filled into a gas bottle for gas chromatography. The gas chromatography detection conditions were as follows:
instrument: agilentGC7890A gas chromatography; chromatographic column: supelco-2560 (100 m 0.25mm ID,0.20 μm film); sample injection setting: the sample injection amount is 1 mu L, the sample injection temperature is 260 ℃, and the split ratio is 50:1; carrier gas: nitrogen, 20cm/s; detector temperature: 260 ℃; column temperature control: the initial temperature is 140 ℃, and the temperature is maintained for 5min; then the temperature was raised to 260℃at a rate of 3℃per minute and maintained for 10 minutes.
The results are shown in FIG. 5, in which SFA content was significantly reduced and PUFA content was significantly increased after the overexpression of CCT. C14:0, C16:0 and C18:0 are the major components of SFA. The C14:0 and C18:0 in the CCT are slightly reduced, the C16:0 is greatly changed, the reduction amplitude is 32% -39%, and the tendency of rising and then falling is presented. PUFAs are the opposite trend, with significant changes in DPA and DHA. SR21 the proportion of DPA and DHA in CCT is lower than S.limacinum SR21 in early stage of cell growth, but is significantly higher than S.limacinum SR21 in middle and later stage of cell growth. Taking the last day (120 h) of fermentation as an example, the ratio of SR21 to C14:0, C16:0 and C18:0 in the total fatty acids of CCT is respectively reduced by 41.08%, 33.60% and 25.31%, and the ratio of DPA and DHA is respectively increased by 78.41% and 45.86%.
5. Isolation and identification of phospholipids
25mg of total lipid was dissolved in 1mL of chloroform/methanol solution (2:1, v/v), 20. Mu.L of PC (19:0/19:0) was added as an internal standard, and Solid Phase Extraction (SPE) with n-hexane added was performed. The nonpolar lipids were eluted with 4mL of two volume ratios (4:1 and 1:1 v/v) of n-hexane/ether solution, respectively. The polar lipids (principally phospholipids) were then filtered with 5mL of methanol and 6mL of a trifluoromethane/methanol/water solution (3:25:2, v/v/v). The obtained phospholipids were then used for UPLC-Q/TOF-MS analysis. Analysis was performed using an ACQUITY UPLC system (Waters Corporation, milford, USA) equipped with a Waters UPLC BEH C chromatographic column (150 mm. Times.2.1 mm. Times.1.7 μm).
The results are shown in FIGS. 4 and 6, wherein the non-polar lipid content of S.limacinum SR21 and SR21 is 81.07% and 77.31% at 48 hours and peaks at 95.41% and 92.72% at 96 hours, respectively. In the fermentation process, the content of the polar lipid of the SR21 is always higher than that of the S.limacinum SR21, and the content of the polar lipid is highest (22.69%) at 48 hours and is 3.9% higher than that of the S.limacinum SR21. Subsequent analysis of the phospholipid composition showed that the phospholipids remained predominantly C16:0, DPA and DHA, consistent with previous results from gas phase detection of various fatty acid components in the phospholipids. The PC mainly comprises PC-C16:0/C22:6, PC-C22:5/C22:6 and PC-C22:6/C22:6. In the wild type, these phospholipid contents decrease significantly over time, whereas in the mutant strain the opposite is true. LPC consists essentially of LPC-C22:5 and LPC-C22:6, which are present in a SR 21:CCT lower than the wild type at 72h, but higher than the wild type at 120 h. PI is mainly composed of PI-C16:0/C22:5 and PI-C16:0/C22:6, and the change is similar to that of PC-C16:0/C22:6. At 120h, the content of PI-C16:0/C22:5 in the SR 21:CCT is obviously changed, and the reduction is about 11%. PG is mainly PG-C16:0/C16:0, and the maximum amplitude reduction is about 7.7% at 72 h. Thus, the CCT strain has significantly increased phospholipid content containing DPA and DHA in the late fermentation stage, while the phospholipid content containing C16:0 is reduced or has no significant change.
In summary, according to the embodiment of the invention, schizochytrium Schizochytrium limacinum SR is adopted as an original strain, a key step of constructing a phospholipid pathway in escherichia coli based on a genetic engineering means, namely a phosphorylcholine cytidine transferase (CCT) gene overexpression vector, then an expression frame with a bleomycin resistance screening gene is inserted into an 18s rDNA locus of an SR21 genome to construct schizochytrium engineering bacteria, and phospholipid metabolic pathways of the schizochytrium engineering bacteria are modified, so that the total grease and the phospholipid content of the engineering bacteria are obviously increased, the accumulation of polyunsaturated fatty acids is increased, the phospholipid ratio is improved by nearly 20% compared with that of the original strain, and the phospholipid ratio is doubled at 120 h; in addition, as the phospholipid is used as an important intermediate in the accumulation process of polyunsaturated fatty acids, the content of PUFAs such as DHA and the like in important phospholipids such as PC/PI is obviously increased, and a theoretical basis is provided for regulating and controlling schizochytrium limacinum to improve fatty acid synthesis.
In the description of the present specification, a description referring to terms "one embodiment," "some embodiments," "examples," "specific examples," or "some examples," etc., means that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the present invention. In this specification, schematic representations of the above terms should not be understood as necessarily being directed to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Further, one skilled in the art can engage and combine the different embodiments or examples described in this specification.
While embodiments of the present invention have been shown and described above, it will be understood that the above embodiments are illustrative and not to be construed as limiting the invention, and that variations, modifications, alternatives and variations may be made to the above embodiments by one of ordinary skill in the art within the scope of the invention.
Claims (5)
1. The genetically engineered bacterium for over-expressing the phosphorylcholine cytidine transferase gene is characterized in that the genetically engineered bacterium is obtained by over-expressing the phosphorylcholine cytidine transferase gene CCT in a starting bacterium; the starting strain is schizochytrium sp S.
limacinum SR21; the nucleotide sequence of the phosphorylcholine cytidine transferase gene is shown as SEQ ID NO: 1.
2. The method for constructing genetically engineered bacteria of claim 1, comprising the steps of:
(1) S.limacinum SR21 genomic DNA is used as a template, and SEQ ID NO:2 and SEQ ID NO:3, PCR amplifying the phosphorylcholine cytidine transferase gene CCT by using the sequence shown in the formula 3 as a primer;
(2) Inserting the phosphorylcholine cytidine transferase gene CCT into a homologous recombination region of a pBlue-zeo-18sUD overexpression vector, and constructing a CCT overexpression vector pBlue-zeo-18sUD-CCT with bleomycin as resistance;
(3) Linearizing the homologous recombination region of the overexpression vector pBlue-zeo-18sUD-CCT, electrically converting into the genome of S.limacinum SR21 for homologous recombination, and screening and identifying the resistance of bleomycin to obtain the genetically engineered bacterium SR21 over-expressing the CCT gene.
3. The use of the genetically engineered bacterium over-expressing a phosphorylcholine cytidine transferase gene as defined in claim 1 in the production of fatty acids.
4. A method for enhancing the metabolism of schizochytrium limacinum phospholipids and improving the production of fatty acids, which is characterized in that the genetically engineered bacterium which overexpresses the phosphorylcholine cytidine transferase gene according to claim 1 is inoculated in a seed culture medium for activation to obtain a strain for fermentation; inoculating the fermentation strain into a fermentation culture medium for fermentation culture, and collecting thalli for identification and analysis of oil components.
5. The method according to claim 4, wherein the genetically engineered bacterium over-expressing the phosphorylcholine cytidine transferase gene is streaked on a solid seed culture medium and subjected to stationary culture at a temperature of 27-29 ℃; selecting a monoclonal on a flat plate to a liquid seed culture medium, and culturing at the temperature of 27-29 ℃ and the speed of 200-250 rpm to obtain first-stage seeds; inoculating the primary seeds into a new liquid seed culture medium according to the inoculum size of 4% -8%, and culturing at the temperature of 27-29 ℃ and the speed of 200-250 rpm to obtain secondary seeds; inoculating the secondary seeds into a fermentation culture medium in an inoculum size of 4% -8%, culturing for 120 hours at the temperature of 27-29 ℃ and the rpm of 200-250 rpm, and sampling every 24 hours in the culturing process for relevant analysis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311560651.1A CN117801968A (en) | 2023-11-21 | 2023-11-21 | Genetically engineered bacterium for over-expressing phosphorylcholine cytidine transferase gene, construction method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311560651.1A CN117801968A (en) | 2023-11-21 | 2023-11-21 | Genetically engineered bacterium for over-expressing phosphorylcholine cytidine transferase gene, construction method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117801968A true CN117801968A (en) | 2024-04-02 |
Family
ID=90424126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311560651.1A Pending CN117801968A (en) | 2023-11-21 | 2023-11-21 | Genetically engineered bacterium for over-expressing phosphorylcholine cytidine transferase gene, construction method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117801968A (en) |
-
2023
- 2023-11-21 CN CN202311560651.1A patent/CN117801968A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11345937B2 (en) | Construction of Mucor circinelloides cell factory for producing stearidonic acid and fermentation technology thereof | |
US11414650B2 (en) | Construction method of Mucor circinelloides cell factory for producing dihomo-gamma-linolenic acid and fermentation technology | |
Bianchi et al. | Antarctic microorganisms as source of the omega-3 polyunsaturated fatty acids | |
CN113265340B (en) | Squalene-producing schizochytrium limacinum genetic engineering strain and construction method and application thereof | |
JP2021520821A (en) | Recombinant yeast strains that produce nervonic acid and their use | |
CN111893049A (en) | Schizochytrium limacinum genetic engineering strain for over-expressing squalene synthetase gene and construction method and application thereof | |
Hong et al. | A transgene expression system for the marine microalgae Aurantiochytrium sp. KRS101 using a mutant allele of the gene encoding ribosomal protein L44 as a selectable transformation marker for cycloheximide resistance | |
WO1998038314A1 (en) | Δ9-desaturase gene | |
CN117801968A (en) | Genetically engineered bacterium for over-expressing phosphorylcholine cytidine transferase gene, construction method and application thereof | |
CN115975823A (en) | Schizochytrium limacinum gene engineering strain with phospholipase D gene knockout function and construction method and application thereof | |
WO2022105841A1 (en) | Use of fatty acid elongase gene and esterase gene in synthesis of nervonic acid and grease in yeast | |
CN115820586A (en) | Lysophosphatidylcholine acyltransferase, nucleic acid molecule and application thereof | |
CN107937362B (en) | DGAT1 gene of cabbage type rape and application thereof | |
CN113512100A (en) | Application of LipR protein and encoding gene thereof in regulation of DHA and oil synthesis | |
KR101107980B1 (en) | Glycogen synthase 1 Gene and Recombinant Vector Comprising the Gene and Host Cell Transformed with the Vector and Manipulation of Fatty Acid Composition and Contents via Glycogen Synthase 1-Defective Cyanobacterium Synechocystis PCC 6803 | |
JP3899397B2 (en) | Method for producing labeled highly unsaturated fatty acids by microorganisms | |
JP4943678B2 (en) | Method for modifying fatty acid composition of cells and use thereof | |
CN109628473A (en) | It is a kind of for improve volume branch Mucor oil production four dicarboxyl acid transporter of carbon | |
CN109628472A (en) | It is a kind of for improve volume branch Mucor oil production dicarboxyl acid transporter | |
CN111321175B (en) | Method for regulating and controlling synthesis of unsaturated fatty acid in synechocystis and application thereof | |
CN114107074B (en) | Construction method and application of schizochytrium limacinum gene engineering strain for over-expressing 3-ketoacyl synthase gene | |
JP4505620B2 (en) | Microorganism producing icosapentaenoic acid and method for producing icosapentaenoic acid | |
CN115125181A (en) | Construction method of menaquinone-7 storage space in bacillus subtilis | |
CN117683650A (en) | Yarrowia lipolytica engineering strain for high-level production of alpha-linolenic acid, construction method and application | |
CN116203166A (en) | Identification method of synthetic pathway of EPA produced by schizochytrium |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |